Source
12 developments in the corpus
Latest
Everything in the corpus, newest first.
OCT 23, 2026 · JOURNAL ARTICLE
Cancer
Abstract Background Obesity is a recognized risk factor for renal cell carcinoma (RCC) incidence, but higher body mass index (BMI) measured at diagnosis has been paradoxically asso
OCT 14, 2026 · JOURNAL ARTICLE
Cancer
Abstract Background The NRG‐GY012 phase 2 trial evaluated olaparib, cediranib, and the combination in 120 patients with recurrent, persistent, or metastatic endometrial cancer (EC)
OCT 6, 2026 · JOURNAL ARTICLE
Cancer
Leptomeningeal disease (LMD) is one of the most devastating complications of advanced non-small cell lung cancer (NSCLC), historically associated with profound neurologic morbidity
Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, and activating KRAS mutations occur in more than 90% of tumors. Direct RAS targeting has moved f
SEP 28, 2026 · JOURNAL ARTICLE
Cancer
ABSTRACT Recent years have seen substantial advances in lung cancer management, with therapeutic options expanding rapidly through the integration of targeted therapies, immunother
SEP 28, 2026 · JOURNAL ARTICLE
Cancer
ABSTRACT Background Progression‐free survival (PFS) is a common primary endpoint in first‐line epithelial ovarian cancer (EOC) trials; however, its relationship with overall surviv
SEP 25, 2026 · JOURNAL ARTICLE
Cancer
Abstract Background Early favorable prostate‐specific antigen (PSA) response to ≤0.2 ng/mL by 6 months is associated with superior overall survival (OS) in metastatic hormone‐sensi
SEP 18, 2026 · JOURNAL ARTICLE
Cancer
Abstract Background Li‐Fraumeni syndrome (LFS) is an inherited cancer predisposition syndrome. Hematologic malignancies are not considered LFS defining tumors, however, both acute